Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vesicare versus Urinacin for idiopathic overactive bladder
IRCT20240504061648N5Phase 3Recruiting
- Sponsor
- Tabriz University of Medical Sciences
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of solifenacin in overactive bladder (OAB) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Treatment-emergent adverse events. Started May 2026; status: recruiting.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on IRCT20240504061648N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240504061648N5.